What Was Danuglipron?
Danuglipron was Pfizer's oral, once-daily GLP-1 receptor agonist (small molecule). Unlike semaglutide or retatrutide — which are peptide molecules requiring injection because they would be degraded in the gastrointestinal tract — danuglipron was a non-peptide small molecule that could be taken as a pill and absorbed through standard oral bioavailability.
The appeal was significant: an oral GLP-1 that could rival semaglutide or tirzepatide in efficacy would dramatically expand access (many patients are needle-averse) and reduce administration burden. Pfizer was betting that convenience would be a major differentiator in the GLP-1 market.
Phase 2 data for danuglipron was encouraging but showed weight loss results that, while meaningful, trailed injectable competitors. Pfizer advanced to Phase 3 trials — then ran into a critical safety problem.
Why Was Danuglipron Discontinued? (April 2025)
Pfizer discontinued danuglipron's Phase 3 program in April 2025 following the identification of potential hepatic toxicity in a Phase 3 participant. Specifically, a participant showed liver enzyme elevations (transaminase elevation) consistent with drug-induced liver injury (DILI) — a serious safety signal that regulators take very seriously.
The decision to halt the program was prudent given the regulatory landscape: DILI is a black-box category for the FDA, and a single confirmed case of serious hepatotoxicity in a Phase 3 trial is typically sufficient to require either program termination or substantial reformulation and additional safety study before proceeding.
Pfizer stated it was discontinuing the program after reviewing the totality of data and the safety signal. This ended a GLP-1 program that had been one of the most watched in the industry given Pfizer's commercial capabilities.
What Happened to Pfizer's Oral GLP-1 Strategy?
Pfizer had been working on multiple approaches to the oral GLP-1 market. The danuglipron discontinuation leaves a significant gap in Pfizer's obesity pipeline. Pfizer had previously discontinued an earlier formulation of danuglipron (twice-daily) due to tolerability concerns, reformulated it as once-daily, and then ultimately discontinued the entire program after the hepatotoxicity signal.
This leaves the oral GLP-1 space to Eli Lilly's orforglipron (a different small-molecule oral GLP-1, now in Phase 3 with FDA submission filed), and Novo Nordisk's oral semaglutide (already approved for T2D as Rybelsus, with ongoing trials for obesity). See our retatrutide vs orforglipron comparison for more on the oral-vs-injectable dynamic within Lilly's own pipeline.
Retatrutide: A Very Different Product Category
Comparing retatrutide and danuglipron directly is somewhat apples-to-oranges: they compete in the obesity drug market broadly, but represent entirely different molecular strategies.
Retatrutide is a peptide triple agonist given by weekly injection. It pursues maximum efficacy through receptor breadth — activating GLP-1, GIP, and glucagon receptors simultaneously. The tradeoff is injection delivery and a more complex tolerability profile (including the TRIUMPH-4 dysesthesia signal).
Danuglipron was a non-peptide small molecule taken orally once daily. It pursued convenience through oral bioavailability — a theoretically massive commercial advantage — but achieved more modest efficacy than injectables, and ultimately succumbed to a hepatic safety signal in Phase 3.
The danuglipron story reinforces that the oral GLP-1 space carries distinct hepatic risks for non-peptide small molecules that do not apply to injectable peptides like retatrutide. The mechanisms of hepatotoxicity for oral small-molecule GLP-1 agonists are under active investigation — it may relate to high hepatic first-pass drug concentrations that peptide injectables avoid entirely.
Implications for the Oral vs Injectable Race
Danuglipron's discontinuation handed Lilly a significant competitive advantage in the oral GLP-1 space. Orforglipron (Lilly's own oral option) has since filed for FDA approval and appears to have a cleaner safety profile in its Phase 3 ATTAIN trials. The key remaining oral competitor is Novo Nordisk's oral semaglutide obesity formulation.
For patients and clinicians watching retatrutide specifically: the danuglipron story has no direct implications for retatrutide's safety or likelihood of approval. Retatrutide is an injected peptide with a different molecular structure, route of administration, and receptor profile — it does not carry the hepatic first-pass concentration risk that affects oral small molecules.
Retatrutide's own safety signals to watch are the TRIUMPH-4 dysesthesia (skin sensation) finding and the Phase 2 lipase elevation signal — neither of which relate to hepatotoxicity.
Sources
- BioSpace — TRIUMPH-4 retatrutide readout (December 2025): Lilly's retatrutide scores triple trial triumph
- ClinicalTrials.gov — retatrutide TRIUMPH program: https://clinicaltrials.gov/search?term=retatrutide
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972